2015
Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics
Kim E, Kim Y, Kang H, Yoon H, Kim W, Kim Y, Yun S, Moon S, Choi Y, Kim I, Lee S, Kim W. Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics. Journal Of Korean Medical Science 2015, 30: 937-942. PMID: 26130958, PMCID: PMC4479949, DOI: 10.3346/jkms.2015.30.7.937.Peer-Reviewed Original ResearchConceptsProstate cancerClinicopathological characteristicsElevated prostate-specific antigen levelsProstate-specific antigen levelBenign prostatic hyperplasia patientsNon-metastatic diseaseAggressive clinicopathologic featuresLow PSA levelsSpecific antigen levelsProstatic hyperplasia patientsAggressive clinicopathological characteristicsLow Gleason scoreHuman prostate cancerCharacteristic curve analysisProstate cancer susceptibilityPSA levelsMetastatic diseasePCa patientsClinicopathologic featuresHyperplasia patientsAntigen levelsGleason scoreClinicopathological parametersPCa tissuesReal-time PCR
2012
Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer
Yun S, Yoon H, Bae S, Lee O, Choi Y, Moon S, Kim I, Kim W. Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer. Prostate Cancer And Prostatic Diseases 2012, 15: 369-373. PMID: 22890388, DOI: 10.1038/pcan.2012.31.Peer-Reviewed Original ResearchConceptsMetastatic diseaseGleason scoreProstate cancerMRNA expressionElevated PSA levelsNon-metastatic diseaseCase-control studyLow Gleason scoreRunx2 expressionHuman prostate tissuePSA levelsBPH patientsClinicopathological characteristicsClinicopathological outcomesCommon cancerLower PSAPrognostic markerReal-time PCRImmunohistochemical stainingImmunohistochemical analysisTranscription factor 2BPH controlProstate tissueRunx2 mRNA expressionCaP aggressiveness
2011
RUNX3 methylation as a predictor for disease progression in patients with non‐muscle‐invasive bladder cancer
Yan C, Kim Y, Ha Y, Kim I, Kim Y, Yun S, Moon S, Bae S, Kim W. RUNX3 methylation as a predictor for disease progression in patients with non‐muscle‐invasive bladder cancer. Journal Of Surgical Oncology 2011, 105: 425-430. PMID: 22311819, DOI: 10.1002/jso.22087.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCarcinoma in SituCarcinoma, Transitional CellChildCore Binding Factor Alpha 3 SubunitDisease ProgressionDNA MethylationDNA, NeoplasmFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPolymerase Chain ReactionPrognosisPromoter Regions, GeneticSurvival RateUrinary Bladder NeoplasmsYoung AdultConceptsDisease progressionRUNX3 methylation statusRUNX3 methylationTumor stageBladder cancerTumor gradeNMIBC progressionInvasive bladder cancer patientsWorse progression-free survivalProgression-free survivalInvasive bladder cancerPoor clinical outcomeKaplan-Meier estimatesBladder cancer patientsMethylation statusNumber of tumorsHypermethylation of RUNX3Methylation-specific polymerase chain reactionNMIBC samplesAdvanced diseaseClinical outcomesClinicopathological characteristicsIndependent predictorsCancer patientsG3 tumorsThe hOGG1 mutant genotype is associated with prostate cancer susceptibility and aggressive clinicopathological characteristics in the Korean population
Yun S, Ha Y, Chae Y, Kim J, Kim I, Kim W. The hOGG1 mutant genotype is associated with prostate cancer susceptibility and aggressive clinicopathological characteristics in the Korean population. Annals Of Oncology 2011, 23: 401-405. PMID: 21515665, DOI: 10.1093/annonc/mdr115.Peer-Reviewed Original ResearchConceptsAggressive clinicopathological characteristicsClinicopathological characteristicsGleason scoreHOGG1 codon 326 genotypesBenign prostatic hyperplasia patientsSer/Ser genotypeProstatic hyperplasia patientsCase-control studyRisk of CaPPeptide nucleic acid-mediated PCR clampingSer/CysProstate cancer susceptibilityWild-type genotypeCAP patientsMetastatic diseaseClinicopathological outcomesHyperplasia patientsTumor stageProstate cancerHigh riskHOGG1 genotypePatientsSer alleleCys alleleKorean population
2010
Tissue hOGG1 Genotype Predicts Bladder Cancer Prognosis: A Novel Approach Using a Peptide Nucleic Acid Clamping Method
Ha Y, Yan C, Kim I, Yun S, Moon S, Kim W. Tissue hOGG1 Genotype Predicts Bladder Cancer Prognosis: A Novel Approach Using a Peptide Nucleic Acid Clamping Method. Annals Of Surgical Oncology 2010, 18: 1775-1781. PMID: 21184188, DOI: 10.1245/s10434-010-1500-7.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerBladder cancerPolymerase chain reactionNonmuscle invasive bladder cancer patientsHOGG1 codon 326 genotypesProgression-free survival benefitInvasive bladder cancer patientsTumor tissueTissue genotypeHOGG1 codon 326Primary BC patientsCox regression analysisInvasive bladder cancerBladder cancer prognosisPrimary bladder cancerAggressive clinicopathological featuresBladder cancer patientsReal-time polymerase chain reactionSurvival benefitBC prognosisClinicopathological characteristicsClinicopathological featuresBC patientsPrognostic indicatorCancer patients